UNASSIGNED: e14108 Background: @entity29 ( @entity29 ) increases the risk of @entity14 . Manipulating the gut microbiota has been proposed to decrease @entity32 and @entity14 . Bacterial species in the VSL#3 mixture are capable of producing conjugated @entity4722 (CLA), a @entity5204 with demonstrated anti-inflammatory and anti-carcinogenic effects. This study aimed to compare the anti-carcinogenic anti-inflammatory efficacies of dietary CLA versus VSL#3 treatment in @entity19 models of @entity29 and @entity694 . METHODS: Following induction of @entity1960 or @entity32 -driven @entity14 @entity19 treated with placebo, CLA or VSL#3 for 30 days were monitored for disease activity over time. Colonic specimens were collected for histopathology, gene expression and flow cytometric analyses. Immune cell subsets in the mesenteric lymph nodes (MLN), spleen, blood and colonic lamina propria lymphocytes (LPL) were phenotypically and functionally characterized. RESULTS: VSL#3 and CLA ameliorated disease activity and reduced colonic inflammatory lesions and @entity5 formation, although VSL#3 was more effective than CLA. Histopathological examination revealed @entity30683 , @entity420 and @entity652 in colons of VSL#3-treated @entity19 when compared to the control and CLA groups, although CLA-treated @entity19 had significantly lower @entity5 and leukocyte infiltration than controls. VSL#3 increased the percentage of @entity636 ( @entity636 ) and @entity3744 expressing T cells in the MLN and colonic LPL, VSL#3 also increased the @entity1961 + @entity3844 + @entity6232 + memory T cells population in the colonic LPL. Gene expression analyses showed that CLA reduced colonic mRNA expression of @entity1996 ( @entity1996 ) and VSL#3 upregulated angiostatin expression. CONCLUSIONS: Both CLA and VSL#3 improved disease activity and reduced colonic inflammatory lesions and @entity5 formation in @entity19 models of @entity29 and @entity32 -induced @entity14 , although VSL#3 showed greater anti-carcinogenic and anti-inflammatory activities than CLA. Mechanistically, CLA modulated expression of @entity1996 levels in the colonic mucosa, whereas VSL#3 targeted regulatory mucosal @entity1961 + T cell responses.

VSL#3 and conjugated @entity4722 ameliorate @entity1960 and @entity32 -driven XXXX .

@entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity5204 :: ('CHEBI:26208', 'Chemical') :: ['polyunsaturated fatty acid'] @entity1996 :: ('19225(Tax:10090)', 'Gene') :: ['COX-2', 'cyclooxygenase 2'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity636 :: ('16171(Tax:10090)', 'Gene') :: ['interleukin 17', 'IL-17'] @entity30683 :: ('MESH:C565155', 'Disease') :: ['lower epithelial erosion'] @entity3844 :: ('12505(Tax:10090)', 'Gene') :: ['CD44'] @entity29 :: ('MESH:D015212', 'Disease') :: ['Inflammatory bowel disease', 'IBD'] @entity1960 :: ('MESH:D003092', 'Disease') :: ['colitis'] @entity1961 :: ('12504(Tax:10090)', 'Gene') :: ['CD4'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity3744 :: ('20371(Tax:10090)', 'Gene') :: ['FoxP3'] @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas'] @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas'] @entity4722 :: ('MESH:D019787', 'Chemical') :: ['linoleic acid'] @entity6232 :: ('20343(Tax:10090)', 'Gene') :: ['CD62L']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']
